Aptorum Group and DiamiR Biosciences Announce Merger Agreement

Aptorum Group ( (APM) ) has provided an announcement.

Aptorum Group Limited and DiamiR Biosciences Corp. announced a definitive all-stock merger agreement on July 14, 2025. The merger aims to create a combined entity focused on brain health diagnostics and therapeutic development, with DiamiR becoming a wholly-owned subsidiary of Aptorum. The merger is expected to enhance the company’s ability to raise capital, expand its neurodiagnostic and therapeutics platforms, and generate revenue through DiamiR’s operational clinical laboratory. The merger is pending regulatory and shareholder approvals, with completion expected in the fourth quarter of 2025.

Spark’s Take on APM Stock

According to Spark, TipRanks’ AI Analyst, APM is a Neutral.

Aptorum Group’s overall stock score of 41 reflects significant financial difficulties, with declining revenues and persistent losses as primary concerns. Technical analysis indicates bearish trends, and valuation metrics suggest the stock may be overvalued. The lack of earnings call and corporate events data leaves these areas unassessed.

To see Spark’s full report on APM stock, click here.

More about Aptorum Group

Aptorum Group Limited is a clinical-stage biopharmaceutical company specializing in oncology, including orphan indications, and infectious diseases. It is listed on NASDAQ under the ticker APM and is dedicated to addressing unmet medical needs through drug discovery and development.

Average Trading Volume: 10,097,038

Technical Sentiment Signal: Hold

Current Market Cap: $12.22M

For a thorough assessment of APM stock, go to TipRanks’ Stock Analysis page.